749913-57-3

Upstream product

• 4746-97-8 cyclohexanedione monoethylene ketal 
• 523980-99-6 1-(2-iodobenzyl)piperazine 

Downstream Products

• 828934-55-0 2-hydroxy-5-[4-(2-iodo-benzyl)-piperazin-1-yl]-cyclohex-1-enecarboxylic acid benzo[1,3]dioxol-4-ylamide 
• 828934-81-2 2-hydroxy-5-[4-(2-iodo-benzyl)-piperazin-1-yl]-cyclohex-1-enecarboxylic acid (2,3-dimethoxy-phenyl)-amide 
• 749913-61-9 {4-[4-(2-iodo-benzyl)-piperazin-1-yl]-cyclohex-1-enyl}-dimethyl-amine 
• 749913-59-5 4-[4-(2-iodo-benzyl)-piperazin-1-yl]-cyclohexanone 

Relevant academic research and scientific papers

Ligand conformation has a definitive effect on 5-HT1A and serotonin reuptake affinity

Conformationally constrained cyclohexanes and cyclohexenes were prepared and tested for 5-HT1A and SSRI activity. The conformation of the dioxyaryl ring with respect to the cyclohexane ring is a key factor for selecting the relative potency of the compounds at the two receptors studied. Conformationally constrained aryl cyclohexanes and cyclohexenes based on aryl cyclohexanols 1 were prepared. Locking the aryl ring in plane with the cyclohexane moiety provided potent SSRIs 3. Conversely, fixing the aryl ring perpendicular to the cyclohexane ring via a spiro lactone provided balanced 5-HT1A antagonists with mid-nanomolar range SSRI potency (compounds 2).